Clostridioides difficile is a toxin-producing bacteria that is a main cause of antibiotic-associated diarrhea. Clostridioides difficile infections (CDI) are associated with disruptions within the gastrointestinal (GI) microbiota which can be further exacerbated by CDI-targeted antibiotic treatment thereby causing recurrent CDI (rCDI) and compounding the burden placed on patients and the healthcare system. Treatment of rCDI consists of antibiotics which can be paired with preventative therapeutics, such as bezlotoxumab or fecal microbiota transplants (FMTs), if sustained clinical response is not obtained. Newer preventative strategies have been recently approved to assist in restoring balance within the GI system with the goal of preventing recurrent infections.
ZhangSPalazuelos-MunozS, et al.Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis. 2016;16, 447(1). doi:10.1186/s12879-016-1786-6
2.
GuhAYMuYWinstonLG, et al.Trends in U.S. burden of Clostridioides difficile infection and outcomes. NEJM. 2020;382:1320-1330. doi:10.1056/NEJMoa1910215
3.
DethiefsenLHuseSSoginML, et al.The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. doi:10.1371/journal.pbio.0060280
4.
JernbergCSullivanAEdlundC, et al.Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. Appl Environ Microbiol. 2005;71(1):501-506. doi:10.1128/AEM.71.1.501-506.2005
5.
FeuerstadtPTheriaultNTillotsonG. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23:132. doi: 10.1186/s12879-023-08096-0
6.
FeuerstadtPNelsonWWDrozdEM, et al.Health care use, and costs of Clostridioides difficile infections in older adults. J Am Med Dir Assoc. 2022;23(10):1721-1728.e19. doi:10.1016/j.jamda.2022.01.075
7.
SongJHKimYS. Recurrent Clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16-24. doi:10.5009/gnl18071
8.
BarbutFRichardAHamadiK, et al.Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38(6):2386-2388. doi:10.1128/JCM.38.6.2386-2388.2000
MaloneDCArmstrongEPGratieD, et al.A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections. Antimic Steward Health Epidemiol. 2023;3(1):e17. doi:10.1017/ash.2022.369
11.
RodriguesRBarberGEAnanthakrishnanAN. A comprehensive study of costs associated with recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2017;38(2):196-202. doi:10.1017/ice.2016.246
12.
LurienneLBandinelliPAGalvainT, et al.Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes. 2020;4:14. doi: 10.1186/s41687-020-0179-1
13.
BarbutFGalperineTVanhemsP, et al.Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcome. 2019;17:6. doi: 10.1186/s12955-019-1081-5
14.
RogersMAGreeneMYoungVB, et al.Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med. 2013;11:121. doi: 10.1186/1741-7015-11-121
15.
BuettiNMarschallJDreesM, et al.Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2022;43(5):553-569. doi:10.1017/ice.2022.87
16.
PakyzALMoczygembaLRVanderWielenLM, et al.Fecal microbiota transplantation for recurrent Clostridium difficile infection: the patient experience. Am J Infect Control. 2016;44(5):554-559. doi:10.1016/j.ajic.2016.01.018
17.
GuilleminIMarrelALambertJ, et al.Patients’ experience and perception of hospital-treated Clostridium difficile infections: a qualitative study. Patient. 2014;7:97-105. doi: 10.1007/s40271-013-0043-y
18.
JohnsonSLavergneVSkinnerAM, et al.Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549
19.
Van PrehnJReigadasEVogelzangEH, et al.Guideline committee of the European study group on Clostridioides difficile. European society of clinical Microbiology and infectious diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27(Suppl 2):S1-S21. doi:10.1016/j.cmi.2021.09.038
20.
KellyCRFischerMAllegrettiJR, et al.ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124-1147. doi:10.14309/ajg.0000000000001278
21.
RodeAAChehriMKrogsgaardLR, et al.Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections. Aliment Pharmacol Ther. 2021;53:999-1009. doi:10.1111/apt.16309
22.
HotaSSSalesVTomlinsonG, et al.Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile Infection: an Open-Label, Randomized Controlled Trial. Clin Infect Dis. 2017;64(3):265-271. doi:10.1093/cid/ciw731
23.
McFarlandLVElmerGWSurawiczCM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769-1775. doi:10.1111/j.1572-0241.2002.05839.x
24.
MaraoloAEMazzitelliMZappuloE, et al.Oral vancomycin prophylaxis for primary and secondary prevention of Clostridioides difficile infection in patients treated with systemic antibiotic therapy: a systematic review, meta-analysis and trial sequential analysis. Antibiotics. 2022;11(2):183. doi:10.3390/antibiotics11020183
25.
KakiRBrooksAMainC, et al.Does extending Clostridium difficile treatment in patients who are receiving concomitant antibiotics reduce the rate of relapse?Internet J Infect Dis. 2016;15(1):1-5. doi:10.5580/IJID.37585
26.
PatelDSenecalJSpellbergB, et al.Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?JAC Antimicrob Resist. 2023;5(1):dlac138. doi: 10.1093/jacamr/dlac138
27.
GueryBMenichettiFAnttilaVJ, et al.EXTEND clinical study group. extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018;18(3):296-307. doi:10.1016/S1473-3099(17)30751-X
28.
SkinnerAMTanXSirbuBD, et al.A tapered-pulsed fidaxomicin regimen following treatment in patients with multiple Clostridioides difficile infection recurrences. Clin Infect Dis. 2021;73(6):1107-1109. doi:10.1093/cid/ciab233
29.
Percentage of People Covered by Medicaid in the United States from 1990 to 2021 [Internet]. Hamburg: Statista; 2022.
30.
WilcoxMHGerdingDNPoxtonIR, et al.Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305-317. doi:10.1056/NEJMoa1602615
31.
OlmedoMKestlerMValerioM, et al.Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience. Rev Española Quimioter. 2022;35(3):279-283. doi:10.37201/req/120.2021
32.
HengelRLRitterTENathanRV, et al.Real-world experience of bezlotoxumab for prevention of Clostridioides difficile Infection: a retrospective multicenter cohort study. Open Forum Infect Dis. 2020;7(4):ofaa097. doi: 10.1093/ofid/ofaa097
33.
DubberkeERGerdingDNKellyCP, et al.Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection. Open Forum Infect Dis. 2020;7(6):ofaa157. doi:10.1093/ofid/ofaa157
34.
Escudero-SanchezRMuriel GarcíaAGarcía FernándezS, et al.Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study. J Antimicrob Chemother. 2022;77(7):1996-2002. doi: 10.1093/jac/dkac106
35.
TheriotCMYoungVB. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol. 2015;69:445-461. doi: 10.1146/annurev-micro-091014-104115
36.
KaakoAAl-AmerMAbdeenY. Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review. Anaerobe. 2019;55:112-116. doi: 10.1016/j.anaerobe.2018.11.010
KhannaSAssiMLeeC, et al.Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile Infection. Drugs. 2022;82:1527-1538. doi: 10.1007/s40265-022-01797-x
39.
FeuerstadtPLouieTJLashnerB, et al.SERO-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386:220-229. doi:10.1056/NEJMoa2106516
40.
SimsMDKhannaSFeuerstadtP, et al.Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection. JAMA Netw Open. 2023;6(2):e2255758. doi:10.1001/jamanetworkopen.2022.55758
41.
GareyKWFeuerstadtPDubberkeER, et al.Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life. Open Forum Infect Dis. 2023;10(3):ofad113. doi:10.1093/ofid/ofad113
42.
StraubTJDiaoLFordC, et al.SER-109, an investigational microbiome therapeutic, reduces abundance of antimicrobial resistance genes in patients with recurrent Clostridioides difficile infection (rCDI) after standard-of-care antibiotics. Open Forum Infect Dis. 2021;8(Suppl 1):S812-S813. doi: 10.1093/ofid/ofab466.1651
43.
SahaSMaraKPardiDS, et al.Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile Infection. Gastroenterology. 2021;160(6):1961-1969.e3. doi:10.1053/j.gastro.2021.01.010
NagarakantiSOrensteinR. Treating Clostridioides difficile: could microbiota-based live biotherapeutic products provide the answer?Infect Drug Resist. 2023;16:3137-3143. doi:10.2147/IDR.S400570
47.
KhannaSKellyCRLouieT, et al.CP101, an investigational orally administered microbiome therapeutic, increases intestinal microbiome diversity and prevents recurrent C. difficile infection: results from a randomized, placebo-controlled trial. 2021. Am J Gastroenterol. 2021;116:S57. doi:10.14309/01.ajg.0000772996.83378.7c
48.
Open-label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects with Recurrence of Clostridium difficile Infection (PRISM-EXT). Bethesda, MA: ClinicalTrials.gov identifier:NCT03497806; 2022. https://classic.clinicaltrials.gov/ct2/show/study/NCT03497806. Accessed 2023 July 30.
LomeliBKGalbraithHSchettlerJ, et al.Multiple-ascending-dose phase 1 clinical study of the safety, tolerability, and pharmacokinetics of CRS3123, a narrow-spectrum agent with minimal disruption of normal gut microbiota. Antimicrob Agents Chemother. 2019;64(1):e01395. doi:10.1128/AAC.01395-19
VillanoSASeiberlingMTatarowiczW, et al.Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother. 2012;56(10):5224-5229. doi:10.1128/AAC.00913-12
53.
GerdingDNMeyerTLeeC, et al.Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection. A randomized clinical trial. JAMA. 2015;313(17):1719-1727. doi:10.1001/jama.2015.3725
54.
KhannaSPardiDSJonesC, et al.RBX7455, a room temperature-stable, orally-administered investigational live biotherapeutic, is safe, effective, and shifts patients’ microbiomes in a phase 1 study for recurrent Clostridioides difficile infections. Clin Infect Dis. 2020;73(7):e1613-e1620. doi: 10.1093/cid/ciaa1430
55.
Kokai-KunJRobertsTCoughlinO, et al.Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis. 2019;19(5):487-496. doi:10.1016/S1473-3099(18)30731-X
56.
LouieTGolanYKhannaS, et al.VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023;329(16):1356-1366. doi:10.1001/jama.2023.4314
